NEW YORK (GenomeWeb) — IMDx said today that it has received three additional licenses for sale and distribution of its molecular tests for the Abbott m2000 platform outside the US and EU.

First, the IMDx C. difficile assay for the qualitative detection of toxigenic Clostridium difficile toxin A and B genes, and the Flu A/B and RSV assay for the qualitative detection of influenza A, influenza B, and respiratory syncytial virus have been approved by Health Canada for sale and distribution in Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.